Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 23 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2
12(52.2%)
Phase 1
7(30.4%)
Phase 3
4(17.4%)
23Total
Phase 2(12)
Phase 1(7)
Phase 3(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials
NCT05126719Phase 2Active Not Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Role: lead

NCT06976190Phase 3Recruiting

A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Role: lead

NCT07138846Phase 3Not Yet Recruiting

A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Cancer

Role: lead

NCT04868162Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Role: lead

NCT04492488Phase 1Active Not Recruiting

A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Role: lead

NCT05754853Phase 3Recruiting

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Role: lead

NCT04924699Phase 2Unknown

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT05751512Phase 3Unknown

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Role: lead

NCT05688605Phase 1Unknown

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Role: lead

NCT05263869Phase 2Unknown

A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer Patients

Role: lead

NCT05338957Phase 1Unknown

A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.

Role: lead

NCT04843709Phase 1Unknown

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Role: lead

NCT04742153Phase 2Unknown

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Role: lead

NCT05141747Phase 2Unknown

A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.

Role: lead

NCT05155839Phase 1Unknown

Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)

Role: lead

NCT05188209Phase 2Unknown

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Role: lead

NCT04838964Phase 2Unknown

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Role: lead

NCT04839510Phase 2Unknown

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Role: lead

NCT04837508Phase 2Unknown

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Role: lead

NCT04941339Phase 1Unknown

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Role: lead